UK Smoking Rates at Historic Low as E-Cigarette Use Increases

Dec.07.2022
UK Smoking Rates at Historic Low as E-Cigarette Use Increases
Smoking in the UK hit an all-time low in 2021, but more people are turning to e-cigarettes, according to data.

New data shows that the number of smokers in the UK reached a historic low last year, but more people are using e-cigarettes.


According to data from the UK's National Statistics Office, approximately 13.3% of people aged 18 or older smoked in 2021, which is lower than the 14.0% reported in 2020.


However, among people aged 16 and above, 7.7% of them reported using e-cigarettes, compared to 6.4% in 2020.


The first record from the UK National Statistics Office about smoking was in 2011, which found that 20.2% of people had smoked at some point.


The UK's National Statistics Office has stated that the latest data represents a "statistically significant" decrease.


Is vaping a risk-free choice? Should disposable e-cigarettes be banned? James Tucker, who works in data analysis for the UK's Office for National Statistics' social care and health department, suggests that the decrease in smokers may partly be due to more people turning to e-cigarettes.


He said, "This is the lowest current smoking rate since 2011, when we began documenting smoking rates through the annual Population Survey (APS).


According to the UK's National Statistics Office, electronic cigarettes and other vaping devices have played a "significant role" in reducing the number of smokers in the UK.


According to the report, the use of electronic cigarettes is highest among current smokers, at 25.3%, followed by former smokers at 15.0%. Only 1.5% of those who have never smoked reported using e-cigarettes.


However, it added that electronic cigarettes may not be the only factor contributing to the decline in smoking. (Translated from Chinese)


This may also be due to increased public awareness campaigns and the implementation of smoke-free policies in places such as bars and offices.


The government's tobacco control program aims to reduce smoking rates among adults in England to 12% or lower by the end of 2022.


According to the UK's National Statistics Office, Scotland currently has the highest proportion of smokers in the country for 2021 at 14.8%, while England has the lowest at 13.0%.


In other locations, Wales and Northern Ireland have reported respective current smoking rates of 14.1% and 13.8%.


By 2021, men are more likely to be current smokers in the UK with a smoking rate of 15.1% compared to women's rate of 11.5%.


Currently, the age group with the most smokers is 25 to 34 years old, accounting for 15.8%, while the lowest is people aged 65 and over, at 8%.


According to the UK's Office for National Statistics, those who are not qualified are currently more likely to smoke, at a rate of 28.2%, compared to those with a degree or equivalent educational qualifications, who have a smoking rate of 6.6%.


According to the NHS website, while electronic cigarettes are not without some risk, that risk is lower than that of traditional cigarettes. However, the long-term effects of using electronic cigarettes have yet to be fully understood.


Selling e-cigarettes to those under the age of 18 is illegal.


2FIRSTS will continue to report on this topic and provide updates on our mobile app, 2FIRSTSAPP. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Managing Director Naeem Shahab Khan met Perlis Mufti Mohd Asri Zainul Abidin on September 17 and presented the company's shift from conventional cigarettes toward alternative products. The mufti said a product could be considered halal if it is clean, its side effects are not harmful or can be controlled, and it does not involve excessive waste. His remarks did not mention IQOS or any other specific PMI product and did not amount to a new product-specific religious ruling. It was at least the second publicly reported engagement between Philip Morris Malaysia and a Malaysian religious institution over cigarette alternatives within six months.
Regulations
Sep.18 by 2Firsts Perspectives
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19